CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Curr Oncol. 2024 Sep 14;31(9):5498-5515. doi: 10.3390/curroncol31090407.
Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic strategy has been cemented as a crucial component of treatment for most of these patients. However, there is a clear efficacy-effectiveness gap whereby patients in the 'real world' seem to have more modest clinical outcomes compared to those enrolled in landmark clinical trials. This gap may be driven by the under-representation of important patient populations, including populations defined by clinical or molecular characteristics. In this review, we summarize the data outlining the evidence of ICIs in patients with poor Eastern Cooperative Oncology Group performance status (ECOG PS), underlying autoimmune disease (AID), older age, active brain metastases (BMs), and molecular aberrations such as mutations, fusions, mutations and fusions.
自九年前美国食品药品监督管理局（FDA）首次批准免疫检查点抑制剂（ICI）用于治疗非驱动基因的非小细胞肺癌（NSCLC）以来，这种治疗策略已成为大多数此类患者治疗的重要组成部分。然而，疗效差距明显，与纳入标志性临床试验的患者相比，“真实世界”中的患者的临床结局似乎较为温和。这种差距可能是由于重要患者人群代表性不足所致，包括基于临床或分子特征定义的人群。在这篇综述中，我们总结了有关 ICI 在以下患者中的应用数据：ECOG 表现状态（PS）较差、潜在自身免疫性疾病（AID）、年龄较大、有活动性脑转移（BMs），以及存在突变、融合、缺失和融合等分子异常的患者。
